Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that it expects top-line results from its Phase 2 Post-Acute Sequelae of COVID-19 (also known as PASC or Long-COVID) exploratory clinical trial to be available in June 2023. This study will assess the potential of the antiviral combination of valacyclovir and celecoxib to provide symptomatic improvements in patients suffering from Long-COVID when added to standard of care therapy. Outcomes being assessed in this study include fatigue, sleep, attention, pain, autonomic function, memory and anxiety.
Related news for (VIRI)
- virios therapeutics, inc. and wex pharmaceuticals, inc. announce business combination to form dogwood therapeutics, inc. (nasdaq: “dwtx”)
- Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
- Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
- Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023